ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 1478
Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 997
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1625
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1777
Incidence and Prevalence of Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Health Management Organization: A 15-Year Study
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1483
Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome
Sjögren's Syndrome Poster II: Clinical Research
9:00AM-11:00AM
Abstract Number: 1364
Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1429
Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 1769
Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1583
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 993
Increase in Prevalence of Psoriasis Arthritis over Time: Analysis of Claims Data from 65 Million People in Germany from 2009 to 2012
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1611
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1733
Increased Differentiation Resistance of Regulatory T Cells to Endoplasmic Reticulum Stress in Systemic Lupus Erythematosus Patients
T Cell Biology and Targets in Autoimmune Disease Poster I
9:00AM-11:00AM
Abstract Number: 1160
Increased Incidence of Upper and Lower Gastrointestinal Events in Patients with Sarcoidosis: A Population-Based Cohort Study
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
9:00AM-11:00AM
Abstract Number: 1667
Increased Levels of BAFF in SLE Patients Correlates with Neutrophil Activation and Autoantibody Production
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 1766
Increased Renal Damage in Hypocomplementemic Patients with ANCA- Associated Vasculitis
Vasculitis Poster II: ANCA-Associated Vasculitis
  • «Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology